Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azithromycin + ampicillin
- Development stage
- Discontinued
- Lead developer
- Assiut University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves the macrolide antibiotic azithromycin and the beta-lactam antibiotic ampicillin, specifically investigated by Assiut University for the management of preterm premature rupture of membranes (PPROM). Azithromycin acts by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis, while ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). The regimen was studied to prolong the latency period (the time from membrane rupture to delivery) and reduce neonatal morbidity. A key clinical trial (NCT04202380) compared different azithromycin dosing protocols (a single 1000 mg dose versus a 5-day course) alongside standard ampicillin therapy. However, the published study from this trial was retracted due to significant concerns regarding data integrity, inconsistencies between the registry and the article, and a lack of evidence for prior ethical approval.
- Brand names
- ZithromaxPrincipen
- Other names
- Azithromycin/Ampicillin combinationAzithromycin-Assiut University-PPROM protocol
02
Targets
PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on azithromycin + ampicillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azithromycin + ampicillin.